Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.02
2% from low
Exchange
OTC Link
CS
Borrow rate
6.50%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — |
| R&D | $484.1K | $936.8K | $2.2M | $1.8M | $3.9M |
| Operating income | −$599.0K | −$5.6M | −$7.2M | −$10.6M | −$16.1M |
| EBITDA | −$599.0K | −$5.6M | −$7.2M | −$16.5M | −$16.1M |
| Net income | −$599.0K | −$8.5M | −$13.0M | −$14.8M | −$18.3M |
| Net margin | — | — | — | — | — |
| EPS (diluted) | -0.06 | -13.42 | -18.81 | -28.73 | -11.00 |
Annual figures · source: Financial Modeling Prep
PAXMEDICA INC
No one on the platform currently holds PXMD.
No tracked institution reports a position in PXMD as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-10-31 | 1-for-17reverse |
No one on the platform has traded PXMD yet.
| $11961 |
| — |
| OZYMFStrategic Partners A/S | $90.00 | +0.00% | $4M | — |
| QBIOQ BioMed Inc. | $0.00 | -0.00% | $14509 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Fundamental analysis of $PXMD (Kuvatris Therapeutics, Inc.) based on financial data and reported results. #PXMD #Kuvatris
View on StockTwits ↗$PXMD Patent approval (Jan 2025) PaxMedica received its first patent approval for an intranasal formulation of suramin used to treat neurological disorders such as autism.
View on StockTwits ↗$PXMD ✅ Bottom line: • Company: still alive • Nasdaq listing: gone • Stock: OTC / extremely risky
View on StockTwits ↗$PXMD company has cancelled all its shares and renamed itself Kuvatris.
View on StockTwits ↗@ProfessorDman1 ATER is trading like it’s forgotten, but the setup is screaming potential. Clean balance sheet, insider support, and a float that can fly. This feels like early $BINI or $PXMD—before volume poured in and everything changed overnight.
View on StockTwits ↗$PXMD PAX-101 looking promising for ASD and HAT. FDA meetings seem positive. Potential game-changer in neurological treatments. Watching closely for NDA submissions. Could be big if approvals come through. a closer look at current performance: https://beyondspx.com/article/paxmedica-inc-otc-pxmd-pioneering-treatments-for-neurological-disorders
View on StockTwits ↗Kids with Autism are Less Prone to Severe Injuries Compared to Those with ADHD $PXMD https://ibn.fm/hMU57 #biomedstocks
View on StockTwits ↗Donald Trump’s Shock at Autism Figures Triggers Discussions on Possible Causes $PXMD https://ibn.fm/D0R9q #biomedstocks #Autism
View on StockTwits ↗$PXMD Paxmedica, Inc. (PXMD): A Promising Biopharmaceutical Company Navigating Challenges https://beyondspx.com/article/paxmedica-inc-pxmd-a-promising-biopharmaceutical-company-navigating-challenges
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.